NCT02751918 - Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2016

Primary Completion Date

August 23, 2019

Study Completion Date

October 31, 2019

Conditions

Ovarian Neoplasms

Interventions

DRUG

Anetumab ravtansine (BAY94-9343)

Anetumab ravtansine will be administered on Day 1 of every 21-day treatment cycle.

DRUG

Pegylated Liposomal Doxorubicin

Pegylated liposomal doxoribicin will be administered on Day 1 of every 21-day treatment cycle.

Trial Locations (9)

The Institute of Oncology, Chisinau

UZ Leuven Gasthuisberg, Leuven

Clinica Universidad de Navarra CUN en Madrid, Madrid

Clínica Universidad de Navarra CUN, Pamplona

Instituto Valenciano de Oncología, Valencia

Oklahoma University Health Science Center, Oklahoma City

Rocky Mountain Cancer Centers, Aurora

Yale University School of Medicine, New Haven

Ciutat Sanitària i Universitaria de la Vall d'Hebron, Barcelona